A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL

Authors :: Craig Davis
Nancy L. Bartlett
Bo Huang
Aron Thall
Roch Houot
Stephen D. Smith
Ronald Levy
Ganesh Mugundu
Ajay K. Gopal
Neil H. Segal
Holbrook E Kohrt
Source :: Journal of Clinical Oncology. 33:3004-3004
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 3004 Background: 4-1BB agonists enhance cytotoxic T-cell and NK cell responses, including antibody-dependent cellular cytotoxicity, resulting in anti-tumor activity in preclinical models. PF-050825...

Subjects :: CD20
Cancer Research
biology
business.industry
Cell
Phase i study
medicine.anatomical_structure
Oncology
Immunology
medicine
biology.protein
Cancer research
Cytotoxic T cell
Rituximab
In patient
Cell-mediated cytotoxicity
business
medicine.drug

Full Text Access

Tools